Search

Displaying results 6331 - 6340 of 9702 in total
  1. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. … It is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity

  2. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides.

  3. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF).

  4. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … [L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017.

    Products: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml
  5. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. … This allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043].

  6. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as

  7. Drug

    Tivantinib

    go.drugbank.com/drugs/DB12200
    Investigational

    Tivantinib has been investigated in Solid Tumors.

  8. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.

  9. Drug

    Temefos

    go.drugbank.com/drugs/DB12231
    Investigational

    Diphos has been used in trials studying the treatment of Plasmodium Falciparum Malaria.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    [FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola